Skip to main content
. 2020 Oct 20;12(10):3048. doi: 10.3390/cancers12103048

Figure 3.

Figure 3

Spider-plot of the HCC cases who were treated with lenvatinib after the failure of immune checkpoint blockade. Decreases of tumor size were observed at the 4th week of the treatment in 30 out of 36 patients (83.3%). Of these, only 4 patients showed increase of tumor size at the 8th week, compared with that at the baseline.